Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced interim Phase 2 results for its investigational mRNA therapeutic ARCT-810 in ornithine transcarbamylase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA